Skip to main content
Top
Published in: Thrombosis Journal 1/2019

Open Access 01-12-2019 | Insulins | Research

Effects of glycemic control and hypoglycemia on Thrombus formation assessed using automated microchip flow chamber system: an exploratory observational study

Authors: Kiyoaki Yamamoto, Takashi Ito, Tomoka Nagasato, Atsushi Shinnakasu, Mihoko Kurano, Aiko Arimura, Hiroshi Arimura, Hiroshi Hashiguchi, Takahisa Deguchi, Ikuro Maruyama, Yoshihiko Nishio

Published in: Thrombosis Journal | Issue 1/2019

Login to get access

Abstract

Background

Thrombus formation is an important factor affecting cardiovascular events and venous thromboembolism in type 2 diabetes. However, it is unclear whether glycemic control reduces thrombogenicity. We investigated the effect of short-term glycemic control (STUDY 1) and hypoglycemia (STUDY 2) on thrombus formation using an automated microchip flow chamber system.

Methods

For STUDY 1, we recruited 10 patients with type 2 diabetes. Before and after 2 weeks of treatment, blood glucose was analyzed with a continuous glucose monitoring system, and thrombogenicity was analyzed with an automated microchip flow chamber system. For STUDY 2, we recruited 10 subjects without diabetes who underwent an insulin tolerance test. We evaluated the change in thrombogenic potential with hypoglycemia.

Results

STUDY1: The mean blood glucose level reduced from 10.1 ± 2.6 to 6.9 ± 0.97 mM (P < 0.01). T10, an indicator of thrombogenicity, significantly attenuated after glycemic control (338 ± 65 vs. 425 ± 117 s, P < 0.05). The attenuation in T10 was significantly correlated with changes in mean blood glucose level after treatment (r = − 0.718, P < 0.05). STUDY 2: Platelet function was enhanced with decreasing blood glucose; increased platelet function was strongly correlated with an increase in epinephrine.

Conclusions

We demonstrated attenuation in thrombogenicity with short-term comprehensive diabetes care and enhancement in thrombogenicity with hypoglycemia, using a new flow chamber system.

Trial registration

UMIN-CTR UMIN 000019899, registered 26-Jan-2015 (STUDY 2).
Appendix
Available only for authorised users
Literature
1.
go back to reference Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–22.CrossRef Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–22.CrossRef
2.
go back to reference Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359:938–49.CrossRef Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359:938–49.CrossRef
3.
go back to reference Gariani K, Mavrakanas T, Combescure C, Perrier A, Marti C. Is diabetes mellitus a risk factor for venous thromboembolism? A systematic review and meta-analysis of case-control and cohort studies. Eur J Intern Med. 2016;28:52–8.CrossRef Gariani K, Mavrakanas T, Combescure C, Perrier A, Marti C. Is diabetes mellitus a risk factor for venous thromboembolism? A systematic review and meta-analysis of case-control and cohort studies. Eur J Intern Med. 2016;28:52–8.CrossRef
4.
go back to reference Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003;26:2181–8.CrossRef Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003;26:2181–8.CrossRef
5.
go back to reference Boden G, Vaidyula VR, Homko C, Cheung P, Rao AK. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J Clin Endocrinol Metab. 2007;92:4352–8.CrossRef Boden G, Vaidyula VR, Homko C, Cheung P, Rao AK. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J Clin Endocrinol Metab. 2007;92:4352–8.CrossRef
6.
go back to reference Seljeflot I, Larsen JR, Dahl-Jorgensen K, Hanssen KF, Arnesen H. Fibrinolytic activity is highly influenced by long-term glycemic control in type 1 diabetic patients. J Thromb Haemost. 2006;4:686–8.CrossRef Seljeflot I, Larsen JR, Dahl-Jorgensen K, Hanssen KF, Arnesen H. Fibrinolytic activity is highly influenced by long-term glycemic control in type 1 diabetic patients. J Thromb Haemost. 2006;4:686–8.CrossRef
7.
go back to reference Newman JD, Wilcox T, Smilowitz NR, Berger JS. Influence of diabetes on trends in perioperative cardiovascular events. Diabetes Care. 2018. Newman JD, Wilcox T, Smilowitz NR, Berger JS. Influence of diabetes on trends in perioperative cardiovascular events. Diabetes Care. 2018.
8.
go back to reference Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.CrossRef Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.CrossRef
9.
go back to reference Fonseca VA, Reynolds T, Hemphill D, Randolph C, Wall J, Valiquet TR, Graveline J, Fink LM. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complicat. 1998;12:181–6.CrossRef Fonseca VA, Reynolds T, Hemphill D, Randolph C, Wall J, Valiquet TR, Graveline J, Fink LM. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complicat. 1998;12:181–6.CrossRef
10.
go back to reference Brass LF, Diamond SL. Transport physics and biorheology in the setting of hemostasis and thrombosis. J Thromb Haemost. 2016;14:906–17.CrossRef Brass LF, Diamond SL. Transport physics and biorheology in the setting of hemostasis and thrombosis. J Thromb Haemost. 2016;14:906–17.CrossRef
11.
go back to reference Hosokawa K, Ohnishi T, Kondo T, Fukasawa M, Koide T, Maruyama I, Tanaka KA. A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions. J Thromb Haemost. 2011;9:2029–37.CrossRef Hosokawa K, Ohnishi T, Kondo T, Fukasawa M, Koide T, Maruyama I, Tanaka KA. A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions. J Thromb Haemost. 2011;9:2029–37.CrossRef
12.
go back to reference Hosokawa K, Ohnishi T, Sameshima H, Miura N, Ito T, Koide T, Maruyama I. Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions. Thromb Haemost. 2013;109:102–11.CrossRef Hosokawa K, Ohnishi T, Sameshima H, Miura N, Ito T, Koide T, Maruyama I. Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions. Thromb Haemost. 2013;109:102–11.CrossRef
13.
go back to reference Hosokawa K, Ohnishi T, Fukasawa M, Kondo T, Sameshima H, Koide T, Tanaka KA, Maruyama I. A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process. Microvasc Res. 2012;83:154–61.CrossRef Hosokawa K, Ohnishi T, Fukasawa M, Kondo T, Sameshima H, Koide T, Tanaka KA, Maruyama I. A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process. Microvasc Res. 2012;83:154–61.CrossRef
14.
go back to reference Yamaguchi Y, Moriki T, Igari A, Matsubara Y, Ohnishi T, Hosokawa K, Murata M. Studies of a microchip flow-chamber system to characterize whole blood thrombogenicity in healthy individuals. Thromb Res. 2013;132:263–70.CrossRef Yamaguchi Y, Moriki T, Igari A, Matsubara Y, Ohnishi T, Hosokawa K, Murata M. Studies of a microchip flow-chamber system to characterize whole blood thrombogenicity in healthy individuals. Thromb Res. 2013;132:263–70.CrossRef
15.
go back to reference Osende JI, Badimon JJ, Fuster V, Herson P, Rabito P, Vidhun R, Zaman A, Rodriguez OJ, Lev EI, Rauch U, et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol. 2001;38:1307–12.CrossRef Osende JI, Badimon JJ, Fuster V, Herson P, Rabito P, Vidhun R, Zaman A, Rodriguez OJ, Lev EI, Rauch U, et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol. 2001;38:1307–12.CrossRef
16.
go back to reference Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–7.CrossRef Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–7.CrossRef
17.
go back to reference Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campaigne BN, Kerr L, Milicevic Z, Jacober SJ. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care. 2009;32:381–6.CrossRef Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campaigne BN, Kerr L, Milicevic Z, Jacober SJ. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care. 2009;32:381–6.CrossRef
18.
go back to reference Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj. 2000;321:405–12.CrossRef Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj. 2000;321:405–12.CrossRef
19.
go back to reference Dunn EJ, Ariens RA, Grant PJ. The influence of type 2 diabetes on fibrin structure and function. Diabetologia. 2005;48:1198–206.CrossRef Dunn EJ, Ariens RA, Grant PJ. The influence of type 2 diabetes on fibrin structure and function. Diabetologia. 2005;48:1198–206.CrossRef
20.
go back to reference Pieters M, Covic N, van der Westhuizen FH, Nagaswami C, Baras Y, Toit Loots D, Jerling JC, Elgar D, Edmondson KS, van Zyl DG, et al. Glycaemic control improves fibrin network characteristics in type 2 diabetes - a purified fibrinogen model. Thromb Haemost. 2008;99:691–700.CrossRef Pieters M, Covic N, van der Westhuizen FH, Nagaswami C, Baras Y, Toit Loots D, Jerling JC, Elgar D, Edmondson KS, van Zyl DG, et al. Glycaemic control improves fibrin network characteristics in type 2 diabetes - a purified fibrinogen model. Thromb Haemost. 2008;99:691–700.CrossRef
21.
go back to reference Hammer MR, John PN, Flynn MD, Bellingham AJ, Leslie RD: Glycated fibrinogen: a new index of short-term diabetic control. Ann Clin Biochem 1989, 26 ( Pt 1):58–62.CrossRef Hammer MR, John PN, Flynn MD, Bellingham AJ, Leslie RD: Glycated fibrinogen: a new index of short-term diabetic control. Ann Clin Biochem 1989, 26 ( Pt 1):58–62.CrossRef
22.
go back to reference Ajjan RA, Gamlen T, Standeven KF, Mughal S, Hess K, Smith KA, Dunn EJ, Anwar MM, Rabbani N, Thornalley PJ, et al. Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity. Blood. 2013;122:134–42.CrossRef Ajjan RA, Gamlen T, Standeven KF, Mughal S, Hess K, Smith KA, Dunn EJ, Anwar MM, Rabbani N, Thornalley PJ, et al. Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity. Blood. 2013;122:134–42.CrossRef
23.
go back to reference Derosa G, Dangelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, et al. Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome. J Int Med Res. 2006;34:545–55.CrossRef Derosa G, Dangelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, et al. Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome. J Int Med Res. 2006;34:545–55.CrossRef
24.
go back to reference Bruno G, Cavallo-Perin P, Bargero G, Borra M, D'Errico N, Pagano G. Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996;125:653–7.CrossRef Bruno G, Cavallo-Perin P, Bargero G, Borra M, D'Errico N, Pagano G. Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996;125:653–7.CrossRef
25.
go back to reference Barazzoni R, Kiwanuka E, Zanetti M, Cristini M, Vettore M, Tessari P. Insulin acutely increases fibrinogen production in individuals with type 2 diabetes but not in individuals without diabetes. Diabetes. 2003;52:1851–6.CrossRef Barazzoni R, Kiwanuka E, Zanetti M, Cristini M, Vettore M, Tessari P. Insulin acutely increases fibrinogen production in individuals with type 2 diabetes but not in individuals without diabetes. Diabetes. 2003;52:1851–6.CrossRef
26.
go back to reference Sam S, Haffner S, Davidson MH, D'Agostino RB Sr, Feinstein S, Kondos G, Perez A, Mazzone T. Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes. Diabetes Care. 2009;32:932–7.CrossRef Sam S, Haffner S, Davidson MH, D'Agostino RB Sr, Feinstein S, Kondos G, Perez A, Mazzone T. Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes. Diabetes Care. 2009;32:932–7.CrossRef
27.
go back to reference Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT angina pectoris study group. Arterioscler Thromb. 1993;13:1865–73.CrossRef Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT angina pectoris study group. Arterioscler Thromb. 1993;13:1865–73.CrossRef
28.
go back to reference Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Torella R. Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia. 1988;31:889–91.CrossRef Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Torella R. Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia. 1988;31:889–91.CrossRef
29.
go back to reference Konya H, Hasegawa Y, Hamaguchi T, Satani K, Umehara A, Katsuno T, Ishikawa T, Miuchi M, Kohri K, Suehiro A, et al. Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus. Metabolism. 2010;59:1294–9.CrossRef Konya H, Hasegawa Y, Hamaguchi T, Satani K, Umehara A, Katsuno T, Ishikawa T, Miuchi M, Kohri K, Suehiro A, et al. Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus. Metabolism. 2010;59:1294–9.CrossRef
30.
go back to reference Singer J, Weissler Snir A, Leshem-Lev D, Rigler M, Kornowski R, Lev EI. Effect of intensive glycemic control on platelet reactivity in patients with long-standing uncontrolled diabetes. Thromb Res. 2014;134:121–4.CrossRef Singer J, Weissler Snir A, Leshem-Lev D, Rigler M, Kornowski R, Lev EI. Effect of intensive glycemic control on platelet reactivity in patients with long-standing uncontrolled diabetes. Thromb Res. 2014;134:121–4.CrossRef
31.
go back to reference Schneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care. 2009;32:525–7.CrossRef Schneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care. 2009;32:525–7.CrossRef
32.
go back to reference Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. Jama. 2008;300:2134–41.CrossRef Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. Jama. 2008;300:2134–41.CrossRef
33.
go back to reference Trovati M, Anfossi G, Cavalot F, Vitali S, Massucco P, Mularoni E, Schinco P, Tamponi G, Emanuelli G. Studies on mechanisms involved in hypoglycemia-induced platelet activation. Diabetes. 1986;35:818–25.CrossRef Trovati M, Anfossi G, Cavalot F, Vitali S, Massucco P, Mularoni E, Schinco P, Tamponi G, Emanuelli G. Studies on mechanisms involved in hypoglycemia-induced platelet activation. Diabetes. 1986;35:818–25.CrossRef
34.
go back to reference Mikhailidis DP, Barradas MA, Jeremy JY, Dandona P. Effect of alpha a-adrenoceptor antagonist on platelet activation during insulin-induced hypoglycaemia in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1989;32:147–9.CrossRef Mikhailidis DP, Barradas MA, Jeremy JY, Dandona P. Effect of alpha a-adrenoceptor antagonist on platelet activation during insulin-induced hypoglycaemia in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1989;32:147–9.CrossRef
35.
go back to reference Takeda H, Kishikawa H, Shinohara M, Miyata T, Suzaki K, Fukushima H, Ichinose K, Shichiri M. Effect of alpha 2-adrenoceptor antagonist on platelet activation during insulin-induced hypoglycaemia in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1988;31:657–63.CrossRef Takeda H, Kishikawa H, Shinohara M, Miyata T, Suzaki K, Fukushima H, Ichinose K, Shichiri M. Effect of alpha 2-adrenoceptor antagonist on platelet activation during insulin-induced hypoglycaemia in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1988;31:657–63.CrossRef
36.
go back to reference Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med. 2013;369:362–72.CrossRef Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med. 2013;369:362–72.CrossRef
37.
go back to reference Kishikawa H, Takeda H, Kiyota S, Sakakida M, Fukushima H, Ichinose K, Matsuda H, Nakamura N, Uzawa H. Role of alpha 2-adrenergic receptor in platelet activation during insulin-induced hypoglycemia in normal subjects. Diabetes. 1987;36:407–12.CrossRef Kishikawa H, Takeda H, Kiyota S, Sakakida M, Fukushima H, Ichinose K, Matsuda H, Nakamura N, Uzawa H. Role of alpha 2-adrenergic receptor in platelet activation during insulin-induced hypoglycemia in normal subjects. Diabetes. 1987;36:407–12.CrossRef
38.
go back to reference Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115:3378–84.CrossRef Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115:3378–84.CrossRef
39.
go back to reference Hutton RA, Mikhailidis D, Dormandy KM, Ginsburg J. Platelet aggregation studies during transient hypoglycaemia: a potential method for evaluating platelet function. J Clin Pathol. 1979;32:434–8.CrossRef Hutton RA, Mikhailidis D, Dormandy KM, Ginsburg J. Platelet aggregation studies during transient hypoglycaemia: a potential method for evaluating platelet function. J Clin Pathol. 1979;32:434–8.CrossRef
40.
go back to reference De Caterina R, Madonna R, Sourij H, Wascher T. Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options. Eur Heart J. 2010;31:1557–64.CrossRef De Caterina R, Madonna R, Sourij H, Wascher T. Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options. Eur Heart J. 2010;31:1557–64.CrossRef
41.
go back to reference Arima Y, Kaikita K, Ishii M, Ito M, Sueta D, Oimatsu Y, Sakamoto K, Tsujita K, Kojima S, Nakagawa K, et al. Assessment of platelet-derived thrombogenicity with the total thrombus-formation analysis system in coronary artery disease patients receiving antiplatelet therapy. J Thromb Haemost. 2016;14:850–9.CrossRef Arima Y, Kaikita K, Ishii M, Ito M, Sueta D, Oimatsu Y, Sakamoto K, Tsujita K, Kojima S, Nakagawa K, et al. Assessment of platelet-derived thrombogenicity with the total thrombus-formation analysis system in coronary artery disease patients receiving antiplatelet therapy. J Thromb Haemost. 2016;14:850–9.CrossRef
42.
go back to reference Idemoto Y, Miura SI, Norimatsu K, Suematsu Y, Hitaka Y, Shiga Y, Morii J, Imaizumi S, Kuwano T, Iwata A, et al. Evaluation of the antithrombotic abilities of non-vitamin K antagonist oral anticoagulants using the Total Thrombus-formation analysis system((R)). Heart Vessel. 2017;32:309–16.CrossRef Idemoto Y, Miura SI, Norimatsu K, Suematsu Y, Hitaka Y, Shiga Y, Morii J, Imaizumi S, Kuwano T, Iwata A, et al. Evaluation of the antithrombotic abilities of non-vitamin K antagonist oral anticoagulants using the Total Thrombus-formation analysis system((R)). Heart Vessel. 2017;32:309–16.CrossRef
43.
go back to reference Ishii M, Kaikita K, Ito M, Sueta D, Arima Y, Takashio S, Izumiya Y, Yamamoto E, Yamamuro M, Kojima S, et al. Direct Oral anticoagulants form Thrombus different from warfarin in a microchip flow chamber system. Sci Rep. 2017;7:7399.CrossRef Ishii M, Kaikita K, Ito M, Sueta D, Arima Y, Takashio S, Izumiya Y, Yamamoto E, Yamamuro M, Kojima S, et al. Direct Oral anticoagulants form Thrombus different from warfarin in a microchip flow chamber system. Sci Rep. 2017;7:7399.CrossRef
Metadata
Title
Effects of glycemic control and hypoglycemia on Thrombus formation assessed using automated microchip flow chamber system: an exploratory observational study
Authors
Kiyoaki Yamamoto
Takashi Ito
Tomoka Nagasato
Atsushi Shinnakasu
Mihoko Kurano
Aiko Arimura
Hiroshi Arimura
Hiroshi Hashiguchi
Takahisa Deguchi
Ikuro Maruyama
Yoshihiko Nishio
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2019
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/s12959-019-0206-8

Other articles of this Issue 1/2019

Thrombosis Journal 1/2019 Go to the issue